You are here

  • Home
  • Archive
  • Volume 10, Issue 8
  • Cost–utility of sofosbuvir/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China

Article info

Article menu

Download PDFPDF

XML
Health economics
Original research
Cost–utility of sofosbuvir/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China

Authors

  • Haoya Yun Centre for Health Management and Policy Research, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, ChinaNHC Key Laboratory of Health Economics and Policy Research, Shandong University, Jinan, China PubMed articlesGoogle scholar articles
  • Guoqiang Zhao Centre for Health Management and Policy Research, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, ChinaNHC Key Laboratory of Health Economics and Policy Research, Shandong University, Jinan, China PubMed articlesGoogle scholar articles
  • Xiaojie Sun Centre for Health Management and Policy Research, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, ChinaNHC Key Laboratory of Health Economics and Policy Research, Shandong University, Jinan, China PubMed articlesGoogle scholar articles
  • Lizheng Shi Department of Health Policy and Management, School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Xiaojie Sun; xiaojiesun{at}sdu.edu.cn
View Full Text

Citation

Yun H, Zhao G, Sun X, et al
Cost–utility of sofosbuvir/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China
BMJ Open 2020;10:e035224. doi: 10.1136/bmjopen-2019-035224

Publication history

  • Received October 23, 2019
  • Revised March 6, 2020
  • Accepted July 8, 2020
  • First published August 20, 2020.
Online issue publication 
July 10, 2023
Previous versions
Review history

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.